Skip to main content
Fig. 5 | Journal of Nanobiotechnology

Fig. 5

From: Exosomes containing miRNAs targeting HER2 synthesis and engineered to adhere to HER2 on tumor cells surface exhibit enhanced antitumor activity

Fig. 5

Antitumor efficacy of exosome-delivered miR-HER2-E1 in vivo. Nude mice bearing SK-OV-3 (a), HCT116 (b) or MDA-MB-231 (c) tumors (the average tumor size was 90 mm3 for each group) were injected intratumorally every three days, 6 times in total (indicated by arrow), with 10 μg of purified exosomes per injection. Tumor size was measured every three days. Results are shown as the mean tumor volume (mm3) ± standard deviation (n = 6). * and *** represent p < 0.05 and p < 0.001 compared with the NT exo group. N.S. indicates no significant difference

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us